Literature DB >> 33933738

Impact of serum calcium levels on total body bone mineral density: A mendelian randomization study in five age strata.

Jing-Yi Sun1, Haihua Zhang2, Yan Zhang3, Longcai Wang4, Bao-Liang Sun5, Feng Gao6, Guiyou Liu7.   

Abstract

BACKGROUND & AIMS: Mendelian randomization (MR) studies have reported the causal association between serum calcium levels and bone mineral density (BMD). The results showed that genetically increased serum calcium levels in individuals with normal calcium levels did not increase BMD and could even reduce BMD. However, whether there are differences in the association between serum calcium and BMD in different age strata remains unclear.
METHODS: We selected eight serum calcium genetic variants with genome-wide significance (P < 5.00E-08) as the potential instrumental variables. We conducted an MR analysis to evaluate the impact of serum calcium levels on total body BMD in five age strata, 0-15, 15-30, 30-45, 45-60, and ≥60 years, using large-scale serum calcium (61,079 individuals) and total body BMD genome-wide association study (66,628 individuals) datasets. For pleiotropy analysis, we used a manual method and four common statistical methods, namely the MR-Egger intercept, MR-PRESSO, heterogeneity, and Steiger filtering tests. For MR analysis, we selected four MR methods, namely inverse-variance weighted, weighted median, MR-Egger, and MR-PRESSO. In addition to the univariable MR analysis, we conducted a multivariate MR analysis taking into account the effect of serum parathyroid hormone levels.
RESULTS: Univariable MR analysis using the inverse-variance weighted method indicated that per 0.5-mg/dL increase (about 1 standard deviation) in serum calcium levels was statistically significantly associated with reduced total body BMD only in the ≥60 years stratum (effect estimate (beta) = -0.545, 95% confidence interval (CI): -0.892 to -0.198, P = 0.002). The weighted median regression (beta = -0.446, 95% CI: -0.821 to -0.094, P = 1.40E-02) and MR-PRESSO (beta = -0.545, 95% CI: -0.892 to -0.198, P = 0.022) MR methods further supported this suggestive association. The multivariable MR analysis also found a significant association between increased serum calcium levels and reduced total body BMD in the ≥60 years stratum (beta = -0.547, 95% CI: -0.934 to -0.16, P = 0.006).
CONCLUSIONS: Our results provide genetic evidence that increased serum calcium levels did not improve BMD in the general population and that the elevated serum calcium levels in generally healthy populations, especially in adults older than 60 years, may even reduce the BMD. Our results are comparable with those of recent MR findings.
Copyright © 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Bone mineral density; Genome-wide association studies; Mendelian randomization; Serum calcium

Year:  2021        PMID: 33933738     DOI: 10.1016/j.clnu.2021.03.012

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  4 in total

1.  Educational Attainment and Ischemic Stroke: A Mendelian Randomization Study.

Authors:  Luyan Gao; Kun Wang; Qing-Bin Ni; Hongguang Fan; Lan Zhao; Lei Huang; Mingfeng Yang; Huanming Li
Journal:  Front Genet       Date:  2022-02-11       Impact factor: 4.599

2.  Total Brain Volumetric Measures and Schizophrenia Risk: A Two-Sample Mendelian Randomization Study.

Authors:  Dan Zhu; Chunyang Wang; Lining Guo; Daojun Si; Mengge Liu; Mengjing Cai; Lin Ma; Dianxun Fu; Jilian Fu; Junping Wang; Feng Liu
Journal:  Front Genet       Date:  2022-03-31       Impact factor: 4.599

Review 3.  A Guide for Understanding and Designing Mendelian Randomization Studies in the Musculoskeletal Field.

Authors:  April E Hartley; Grace M Power; Eleanor Sanderson; George Davey Smith
Journal:  JBMR Plus       Date:  2022-09-20

4.  Mendelian randomization analysis of the causal association of bone mineral density and fracture with multiple sclerosis.

Authors:  Yu Yao; Feng Gao; Yanni Wu; Xin Zhang; Jun Xu; Haiyang Du; Xintao Wang
Journal:  Front Neurol       Date:  2022-09-15       Impact factor: 4.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.